Diagnosis and Management of Gastroesophageal Reflux Disease
Official guideline from the American College of Gastroenterology.
summary by Rachel Niec, MD Rachel Engelberg, MD
Diagnosis
Establishing diagnosis
Diagnostic evaluation is required if non-cardiac chest pain suspicious for GERD. Exclude cardiac causes before evaluating GERD.
Endoscopy for typical GERD is recommended if alarm symptoms, and for screening if high risk for Barrett’s esophagus.
Ambulatory reflux monitoring is indicated before considering endoscopic or surgical therapy if refractory symptoms, or if GERD diagnosis is questionable.
Extraesophageal presentation
Extraesophageal GERD symptoms include asthma, chronic cough, or laryngitis.
PPI trial indicated in patients if extraesophageal symptoms and typical GERD symptoms.
Management
Medical
Lifestyle modifications (weight loss, elevate head of bed, avoid food 2-3 hrs before bedtime) may be recommended in the appropriate clinical setting.
Routine global elimination of trigger foods is not recommended.
PPI (8-week course, once daily 30 mins before breakfast) is initial therapy for symptoms and erosive esophagitis.
PPI can be increased to twice daily dosing or switched if initial therapy has partial response.
Maintenance PPI should be given if symptoms resume after initial therapy or for erosive esophagitis or Barrett’s esophagus.
Maintenance H2RA can be given for heartburn relief if no erosive disease.
GERD Refractory to PPIs
Upper endoscopy is indicated to rule out non-GERD etiologies if typical symptoms.
ENT, pulmonary, and allergy evaluation indicated in patients if extraesophageal GERD symptoms or if typical symptoms and negative upper endoscopy.
pH monitoring is indicated in patients with unexplained GERD despite 1-3 above.
Surgical
Surgery is as effective as medical therapy for carefully selected patients with chronic GERD.
Manometry and ambulatory pH monitoring are required before fundoplication.
Risks and Complications
PPI risks
Patients with known osteoporosis can remain on PPI therapy.
PPIs should be carefully used in patients at risk for Clostridium difficile infection.
Short-term PPI may increase CAP risk. Long-term use has not been shown to increase risk.
Complications
The LA classification system should be used to describe erosive esophagitis.
LA Grade A patients should have further testing.
Repeat endoscopy should be performed after PPI therapy to exclude Barrett’s esophagus if severe esophagitis.
Patients with peptic stricture dilation or Schatzki ring dilation should be placed on continuous PPI.
Intralesional corticosteroids can be used in refractory GERD stricture.
High-risk GERD patients should be screened for Barrett’s esophagus.
What do the icons mean?
How strong is the ACG's recommendation?
Strong recommendation
Intervention's desirable effects clearly outweigh undesirable effects.Moderate recommendation
Further research likely to impact confidence in estimate of effect.Conditional recommendation
Uncertainty in tradeoffs between desirable & undesirable effects of intervention.Weak recommendation
Uncertainty in tradeoffs between desirable & undesirable effects of intervention.High quality evidence
Further research unlikely to change guideline authors' confidence in estimate of effect.Moderate-high quality evidence
Between high and moderate levels of evidence.Moderate quality evidence
Further research likely to impact confidence in estimate of effect.Low quality evidence
Further research expected to have important impact in confidence in estimate of effect.Very low quality evidence
Effect is very uncertain.Literature